The Dr. Zou's CPI lab is directed by Dr. Qing Zou and it works closely with a cross-disciplinary team (clinicians, scientists, fellows) to develop and translate novel MRI techniques for cardiopulmonary MRI for patients with congenital and acquired heart diseases. The research involves different aspects of MRI, including image acquisition and reconstruction, post-processing, quantitative image analysis, pre-clinical investigation, and clinical translation and evaluation. The lab has access to a cardiac-dedicated clinical 1.5T scanner (Philips), a research-dedicated low-field 0.55T MR scanner (Siemens), three research-dedicated 3T scanners (Philips, Siemens, GE). The lab also has access to a high-field 7T research scanner (Philips) for research on the high-field scanner. Some of the scanners also have the capability to do multi-nuclear imaging.

Harnessing the power of light to develop methods to understand, diagnose, & treat diseases. The unique strength of the Achilefu Lab (Optical Radiology Lab, ORL) is the ability to develop complete solutions from conception, implementation, and validation to human clinical care. We aim to change the way medicine is practiced.

Multidisciplinary research to beat cancer

SPIL is dedicated to advancing patient care through the development and validation of cutting-edge radionuclide imaging technologies for single photon emission computed tomography (SPECT) and positron emission tomography (PET). By harnessing the power of deep learning, we aim to address key limitations of PET and SPECT imaging—such as low spatial resolution and slow data acquisition—to significantly enhance diagnostic capabilities.

The Saha Lab.

Zaman’s Lab focuses on the design and development of novel cutting-edge multi-mode imaging systems to overcome current limitations in clinical systems. Most recent research project is involved with the design and developed of a multimode catheter-based imaging system called a Circumferential Intravascular Radioluminescence Photoacoustic Imaging (CIRPI) for early detection of thin-cap-fibro-atheroma (TCFA), the underlying causes of coronary artery disease, one of the leading causes of morbidity and mortality in the USA and worldwide. Further, the CIRPI system characterizes the plaques based on disease tissue compositions to unravel their complex structures. This CIRPI system integrates optical, photoacoustic, radioluminescence and ultrasound imaging. We seek to better understand the underlying causes of the disease mechanisms. We are dissecting the role of TCFA perturbations on vascular wall processes during atherosclerosis progression. Our lab also studying novel molecular imaging methods to study coronary arterial disease, carotid stenosis, and myocardial ischemia in subcellular level.

The Sharma Lab is interested in investigating intermediary metabolism utilizing carbon-13 stable isotope tracers in conjunction with magnetic resonance spectroscopy (MRS), magnetic resonance imaging (MRI), and mass spectrometry (MS).

Translational biophotonics for noninvasive detection of systemic disease.

The Liu Lab is Interested in developing and evaluating novel therapies, notably targeting tumor vasculatures.

We investigate genetic and molecular basis of phenotypic diversity observed in nature by using a range of methodologies such as whole genome sequencing, fluidics, long-term evolution experiments, and large-scale combinatorial mutagenesis.